Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Chantepie

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie CellulaireA Le Bourgeois, M Labopin, D Blaise, et al.
Leukemia & Lymphoma|February 18, 2021
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemiaS Fodil, E Raffoux, P Y Dumas, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie CellulaireA Le Bourgeois, M Labopin, D Blaise, et al.
Leukemia & Lymphoma|February 18, 2021
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemiaS Fodil, E Raffoux, P Y Dumas, et al.
Pageof 2